Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

@article{Adamski2010RiskSA,
  title={Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers},
  author={J. Adamski and B. Godman and G. Ofierska-Sujkowska and Bogusława Osińska and H. Herholz and Kamila Wendykowska and O. Laius and S. Jan and C. Sermet and Corrine Zara and Marija Kalaba and Roland Gustafsson and K. Garuolienė and A. Haycox and S. Garattini and L. Gustafsson},
  journal={BMC Health Services Research},
  year={2010},
  volume={10},
  pages={153 - 153}
}
BackgroundThere has been an increase in 'risk sharing' schemes for pharmaceuticals between healthcare institutions and pharmaceutical companies in Europe in recent years as an additional approach to provide continued comprehensive and equitable healthcare. There is though confusion surrounding the terminology as well as concerns with existing schemes.MethodsAliterature review was undertaken to identify existing schemes supplemented with additional internal documents or web-based references… Expand
Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
TLDR
It is argued that while CA and P4P have a potential to reduce payers' expenditure on costly drugs while maintaining a high list price, CED address initial uncertainty related to assessing the real-life value of new drugs and enable a final HTA recommendation or reimbursement and pricing decisions. Expand
Risk-sharing agreements, present and future
TLDR
There is a tendency for the risk-sharing agreements established between payers and pharmaceutical companies to include a component of monitoring the use of medicines and outcomes measurement, involving real life data collection, in countries where most agreements are still financial in nature. Expand
Overview of Risk-Sharing Schemes: Focusing on Anticancer Drugs
This article aimed to introduce 'risk sharing' schemes for pharmaceuticals between drug manufacturers and healthcare payer. Published literature review was undertaken to summarize risk sharingExpand
Health Affairs Proving Hard To Implement Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are
Risk-sharing agreements, under which payers and pharmaceutical manufacturers agree to link payment for drugs to health outcomes achieved, rather than the volume of products used, offer an appealingExpand
Shifting the Risk in Pricing and Reimbursement Schemes? A Model of Risk-Sharing Agreements for Innovative Drugs
Risk sharing is becoming an increasingly popular instrument to regulate the price of new drugs. In the recent past, forms of risk-sharing agreements between the public regulator and the industry haveExpand
Health-based pharmaceutical pay-for-performance risk-sharing agreements
TLDR
This paper model a risk-sharing agreement in which a proportion of total sales is rebated and examines the performance of this risk- sharing agreement from the manufacturer’s perspective and investigates the conditions under which the manufacturer will make a profit. Expand
Managed entry agreements for pharmaceuticals in Australia.
TLDR
In Australia, a number of managed entry agreements have been developed to enable national coverage of new medicines and the possibility of a randomised controlled trial (RCT)-based entry scheme has yet to be trialed. Expand
The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
TLDR
A systematic literature search in MEDLINE from 2000 to April 2019 found over 20 studies proposed different taxonomies of risk-sharing contracts, which can be summarised as financial and paying-for-performance agreements. Expand
Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
TLDR
The perception exposed by participants that risk-sharing can be a tool for improving the accuracy of early budget-impact estimates and the challenges pointed by them are relevant to other health care systems also and should be considered when implementing similar schemes. Expand
Stakeholder Views of Managed Entry Agreements: A Literature Review of National Studies
Abstract Access to highly expensive and innovate medicine is a challenge. Managed entry agreements/ arrangements (MEAs) consist of various forms of confidential agreements between pharmaceuticalExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 132 REFERENCES
Setting the stage for risk-sharing agreements: International experiences and outcomes-based reimbursement
TLDR
A risk-sharing agreement is a useful tool to manage the risk of introducing clinically effective and very expensive medicines into the healthcare market and is also a tool that bridges the conflicting priorities of the manufacturer of biological medicine and the payer. Expand
Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
TLDR
The extent of use of special pricing arrangements in Australia and how and where they are communicated to health professionals and the community is assessed. Expand
Risk-sharing agreements for innovative drugs
TLDR
The pros and cons of risksharing for both parties involved, the payer and the industry are discussed, and the prerequisites to its implementation are considered. Expand
Soft regulations in pharmaceutical policy making
TLDR
This paper reviews current and future strategies to help improve the quality and efficiency of care, with special emphasis on demand-side controls for pharmaceutical prescribing, and hopes this opinion paper is the first step in the process to develop and implement new demand- side initiatives building on existing ’soft regulations’. Expand
Risk Sharing and Payment by Results
To the Editor: All health-care systems are facing increasing difficulty in finding the resources to meet the demands of their populations for new high-cost technologies. One response has been theExpand
Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.
TLDR
Possible future initiatives could include adopting more stringent criteria for categorizing new drugs as innovative as well as further reductions in the prices of generics and further enhancement of the quality and efficiency of prescribing. Expand
Funding the Unfundable
TLDR
This is the first attempt at a comprehensive analysis of methods that have been used to address uncertainty concerning a new drug or other technology and reveals that, although various approaches have been experimented with, many of them have not achieved the ostensible goal of the approach. Expand
Current National Initiatives and Policies to Control Drug Costs in Europe: UK Perspective
TLDR
NICE has met with variable success, with a number of activities and measures proposed to enhance its contribution, and ongoing reforms will continue with an aging population and pressure on resources. Expand
Pharmaceutical policies: effects of financial incentives for prescribers.
TLDR
Based on the evidence in this review from three Western European countries, drug budgets for physicians in private practice can limit drug expenditure by limiting the volume of prescribed drugs, increasing the use of generic drugs or both. Expand
Generic medicines from a societal perspective: Savings for health care systems?
Background and conventional thinking Given the intense debate surrounding health care cost containment and efficiency in health care resource allocation, it is not surprising that generic policy hasExpand
...
1
2
3
4
5
...